Literature DB >> 22957407

Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?

Dan G Duda1, Christopher G Willett.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22957407      PMCID： PMC3682651     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  18 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).

Authors:  Alice Dewdney; David Cunningham; Josep Tabernero; Jaume Capdevila; Bengt Glimelius; Andres Cervantes; Diana Tait; Gina Brown; Andrew Wotherspoon; David Gonzalez de Castro; Yu Jo Chua; Rachel Wong; Yolanda Barbachano; Jacqueline Oates; Ian Chau
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

Review 3.  CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Authors:  Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

4.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

Review 5.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

6.  C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells.

Authors:  Sachie Hiratsuka; Dan G Duda; Yuhui Huang; Shom Goel; Tatsuki Sugiyama; Takashi Nagasawa; Dai Fukumura; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

7.  KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

Authors:  Philipp Erben; Philipp Ströbel; Karoline Horisberger; Juliana Popa; Beatrice Bohn; Benjamin Hanfstein; Georg Kähler; Peter Kienle; Stefan Post; Frederik Wenz; Andreas Hochhaus; Ralf-Dieter Hofheinz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

8.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Linda H Colangelo; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Richard M Goldberg; Seamus O'Reilly; Luis Chu; Catherine A Azar; Samia Lopa; Norman Wolmark
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 9.  Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?

Authors:  Sergey V Kozin; Dan G Duda; Lance L Munn; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2012-05-09       Impact factor: 13.506

10.  Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Authors:  Jeffrey A Meyerhardt; Marek Ancukiewicz; Thomas A Abrams; Deborah Schrag; Peter C Enzinger; Jennifer A Chan; Matthew H Kulke; Brian M Wolpin; Michael Goldstein; Lawrence Blaszkowsky; Andrew X Zhu; Meaghan Elliott; Eileen Regan; Rakesh K Jain; Dan G Duda
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.